Arvinas, Inc (ARVN) — Analysis Summary
Arvinas, Inc (ARVN) has a market cap of $518.11M with year-over-year revenue growth of -0.3%. Net margin stands at -30.8%. The stock trades at a P/E ratio of -2.3.
Key Takeaways
- Revenue changed -0.3% year-over-year
- Net margin of -30.8%
- P/E ratio of -2.3
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ARVN posted revenue growth of -0.3% and trades at a P/E of -2.3.
Arvinas, Inc (ARVN)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -283.8% — severe operating losses
Net margin at -247.5% — losses exceed revenue (possible one-time charges)
Revenue fell 66.0% vs the prior period.
Net income fell 173.9% vs the prior period.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
246
Headquarters
NEW HAVEN, CT
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.